[Skip to Content]
[Skip to Content Landing]
Article
December 1935

MAPHARSEN ("ARSENOXIDE") IN THE THERAPY OF EXPERIMENTAL SYPHILIS AND TRYPANOSOMIASIS

Arch Derm Syphilol. 1935;32(6):848-867. doi:10.1001/archderm.1935.01470060013002
Abstract

After the synthesis of arsphenamine by Ehrlich and Bertheim1 and its successful introduction by Ehrlich and Hata2 in the therapy of spirillosis and by Wechselmann3 and Uhlenhuth and Mulzer4 in the treatment of syphilis, a considerable attempt has been made to ascertain the mode of action of the arsphenamines. Ehrlich and Hata2 stated that arsphenamine exerted no direct action in the test tube on spirochetes of relapsing fever. Plaut,5 Truffi and Sabbia6 and Bronfenbrenner and Noguchi7 were not able to kill Spirochaeta pallida in the test tube with high concentrations of arsphenamine. Ehrlich and Bertheim1 assumed that the active principle was a product of the breaking down of arsphenamine, the "arsenoxide." Voegtlin and Smith8 produced convincing evidence that the action of the various arsphenamines depends on their conversion into one type, the trivalent oxides with the structure R-AsO, and

First Page Preview View Large
First page PDF preview
First page PDF preview
×